Arcadia Biosciences, Inc. (RKDA): Price and Financial Metrics

Arcadia Biosciences, Inc. (RKDA): $1.03

0.03 (+3.26%)

POWR Rating

Component Grades













Add RKDA to Watchlist
Sign Up

Industry: Agriculture



in industry


  • Sentiment is the dimension where RKDA ranks best; there it ranks ahead of 65.18% of US stocks.
  • RKDA's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • RKDA ranks lowest in Stability; there it ranks in the 0th percentile.

RKDA Stock Summary

  • Of note is the ratio of Arcadia Biosciences Inc's sales and general administrative expense to its total operating expenses; 98.63% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of -60.01%, Arcadia Biosciences Inc's debt growth rate surpasses only 5.46% of about US stocks.
  • As for revenue growth, note that RKDA's revenue has grown 789.32% over the past 12 months; that beats the revenue growth of 98.75% of US companies in our set.
  • Stocks that are quantitatively similar to RKDA, based on their financial statements, market capitalization, and price volatility, are PLAB, OSUR, SMWB, ITT, and AVEO.
  • Visit RKDA's SEC page to see the company's official filings. To visit the company's web site, go to

RKDA Valuation Summary

  • In comparison to the median Basic Materials stock, RKDA's EV/EBIT ratio is 227.63% lower, now standing at -19.4.
  • RKDA's EV/EBIT ratio has moved down 0.6 over the prior 77 months.
  • Over the past 77 months, RKDA's price/earnings ratio has gone down 59.3.

Below are key valuation metrics over time for RKDA.

Stock Date P/S P/B P/E EV/EBIT
RKDA 2021-09-03 5.3 1.2 -73.6 -19.4
RKDA 2021-09-02 5.3 1.2 -73.9 -19.7
RKDA 2021-09-01 5.3 1.2 -73.6 -19.4
RKDA 2021-08-31 5.5 1.3 -77.2 -22.6
RKDA 2021-08-30 5.6 1.3 -77.7 -23.1
RKDA 2021-08-27 5.2 1.2 -72.3 -18.3

RKDA Growth Metrics

    Its 3 year price growth rate is now at -85.1%.
  • Its 4 year revenue growth rate is now at -75.78%.
  • Its 5 year cash and equivalents growth rate is now at -56.08%.
Over the past 33 months, RKDA's revenue has gone up $10,275,000.

The table below shows RKDA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 11.739 -25.959 3.52
2021-06-30 9.677 -24.61 -0.696
2021-03-31 8.553 -25.655 -5.124
2020-12-31 8.034 -30.218 -4.655
2020-09-30 1.32 -28.479 -19.798
2020-06-30 1.398 -25.317 -27.594

RKDA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RKDA has a Quality Grade of D, ranking ahead of 12.03% of graded US stocks.
  • RKDA's asset turnover comes in at 0.174 -- ranking 14th of 16 Agriculture stocks.
  • CVGW, SISI, and ALCO are the stocks whose asset turnover ratios are most correlated with RKDA.

The table below shows RKDA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.174 0.378 -0.027
2021-03-31 0.180 0.307 -0.180
2020-12-31 0.212 0.353 -0.196
2020-09-30 0.039 -2.048 -0.944
2020-06-30 0.040 -0.688 -1.479
2020-03-31 0.041 0.273 -0.884

RKDA Price Target

For more insight on analysts targets of RKDA, see our RKDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.23 Average Broker Recommendation 1.5 (Moderate Buy)

RKDA Stock Price Chart Interactive Chart >

Price chart for RKDA

RKDA Price/Volume Stats

Current price $1.03 52-week high $3.18
Prev. close $1.00 52-week low $0.74
Day low $0.96 Volume 92,500
Day high $1.06 Avg. volume 1,693,779
50-day MA $1.12 Dividend yield N/A
200-day MA $1.39 Market Cap 22.85M

Arcadia Biosciences, Inc. (RKDA) Company Bio

Arcadia Biosciences, Inc. develops and commercializes agricultural products that enhance the environment and human health. It offers crop productivity and product quality traits for various crops. The company was founded in 2002 and is based in Davis, California.

RKDA Latest News Stream

Event/Time News Detail
Loading, please wait...

RKDA Latest Social Stream

Loading social stream, please wait...

View Full RKDA Social Stream

Latest RKDA News From Around the Web

Below are the latest news stories about Arcadia Biosciences Inc that investors may wish to consider to help them evaluate RKDA as an investment opportunity.

Arcadia Biosciences hires brand marketing veteran Jacot as CEO

Arcadia Biosciences Inc. has hired a food and brand marketing veteran as its new CEO. Stan Jacot, previously president of Jane’s Dough Foods in the Columbus, Ohio area, became CEO on Wednesday. Jacot has had senior marketing and operations roles at Mission Foods in Texas, Borden Dairy Co., ConAgra Brands Inc. (NYSE: CAG) and Kellogg Co. (NYSE: K).

Yahoo | February 3, 2022

Arcadia Biosciences appoints CEO

Arcadia Biosciences (RKDA) appointed consumer veteran Stan Jacot as CEO effective Feb. 2

Seeking Alpha | February 2, 2022

Arcadia Biosciences (RKDA) Names Stan Jacot as CEO

Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, has appointed veteran consumer goods leader Stan Jacot as chief executive officer, effective today.

Yahoo | February 2, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, trader!

William White on InvestorPlace | January 5, 2022

H.C. Wainwright Thinks Arcadia Biosciences’ Stock is Going to Recover

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Arcadia Biosciences (RKDA – Research Report), with a price target of $6.00. The company's shares closed last Friday at $1.04, close to its 52-week low of $0.99. According to, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.5% and a 25.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. Currently, the analyst consensus on Arcadia Biosciences is a Moderate Buy with an average price target of $5.25.

Howard Kim on TipRanks | January 3, 2022

Read More 'RKDA' Stories Here

RKDA Price Returns

1-mo -23.70%
3-mo -46.63%
6-mo 3.00%
1-year -65.67%
3-year -66.45%
5-year -89.04%
YTD -0.96%
2021 -58.89%
2020 -53.83%
2019 72.87%
2018 -42.36%
2017 -70.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7042 seconds.